Obesity Drug Stumble Costs Novo Nordisk $60 Billion in One Day

The weight loss drug market took a turn on December 20, 2024. Novo Nordisk, the Danish pharmaceutical giant, saw its stock plummet by nearly 30% after its new obesity drug fell short of expectations. This single-day drop erased $60 billion from the company’s market value. Novo Nordisk’s experimental drug, CagriSema, achieved a 22.7% average weight […]